{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hong SY"],"funding":["World Health Organization","NIAID NIH HHS","PHS HHS"],"pagination":["463-71"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4334707"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["68(4)"],"pubmed_abstract":["<h4>Objective</h4>The World Health Organization (WHO) prospective surveys of acquired HIV drug resistance (HIVDR) evaluate HIVDR emerging after the first year of antiretroviral therapy (ART) and associated factors.<h4>Methods</h4>Consecutive ART starters in 2009 were enrolled at 3 sentinel sites in Namibia. Genotyping was performed at start and after 12 months in patients with HIV viral load (VL) >1000 copies per mL. HIVDR outcomes were: HIVDR prevention (VL ≤1000 copies/mL), possible HIVDR (VL >1000 copies/mL without detectable HIVDR or loss to follow-up or ART stop), and HIVDR (VL >1000 copies/mL with detectable HIVDR). Adherence was assessed using medication possession ratio (MPR).<h4>Results</h4>Of 394 starters, at 12 months, 80% were on first-line ART, 1% died, 4% transferred out, 1% "],"journal":["Journal of acquired immune deficiency syndromes (1999)"],"pubmed_title":["Population-based surveillance of HIV drug resistance emerging on treatment and associated factors at sentinel antiretroviral therapy sites in Namibia."],"pmcid":["PMC4334707"],"funding_grant_id":["001","1K23AI097010-01A1","K23 AI097010","K23 AI074423","P30 AI042853","L30 AI080268-02","L30 AI080268","T32 AI007438","T32 AI007438-16","K23 AIO74423-05"],"pubmed_authors":["Badi A","Wanke C","Tang AM","Trotter A","Hong SY","Jonas A","DeKlerk M","Sheehan HB","Ledwaba J","Morris L","Lau K","Desta T","Hunt GM","Shiningavamwe A","Jordan MR"],"additional_accession":[]},"is_claimable":false,"name":"Population-based surveillance of HIV drug resistance emerging on treatment and associated factors at sentinel antiretroviral therapy sites in Namibia.","description":"<h4>Objective</h4>The World Health Organization (WHO) prospective surveys of acquired HIV drug resistance (HIVDR) evaluate HIVDR emerging after the first year of antiretroviral therapy (ART) and associated factors.<h4>Methods</h4>Consecutive ART starters in 2009 were enrolled at 3 sentinel sites in Namibia. Genotyping was performed at start and after 12 months in patients with HIV viral load (VL) >1000 copies per mL. HIVDR outcomes were: HIVDR prevention (VL ≤1000 copies/mL), possible HIVDR (VL >1000 copies/mL without detectable HIVDR or loss to follow-up or ART stop), and HIVDR (VL >1000 copies/mL with detectable HIVDR). Adherence was assessed using medication possession ratio (MPR).<h4>Results</h4>Of 394 starters, at 12 months, 80% were on first-line ART, 1% died, 4% transferred out, 1% ","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Apr","modification":"2025-06-28T03:05:15.196Z","creation":"2025-06-28T03:05:15.196Z"},"accession":"S-EPMC4334707","cross_references":{"pubmed":["25564107"],"doi":["10.1097/qai.0000000000000509","10.1097/QAI.0000000000000509"]}}